Home » Stocks » CELC

Celcuity Inc. (CELC)

Stock Price: $23.16 USD -0.86 (-3.58%)
Updated Apr 20, 2021 4:00 PM EDT - Market closed
After-hours: $23.00 -0.16 (-0.69%) Apr 20, 5:43 PM
Market Cap 286.19M
Revenue (ttm) n/a
Net Income (ttm) -9.47M
Shares Out 12.29M
EPS (ttm) -0.92
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 20
Last Price $23.16
Previous Close $24.02
Change ($) -0.86
Change (%) -3.58%
Day's Open 23.89
Day's Range 22.81 - 23.94
Day's Volume 86,030
52-Week Range 4.46 - 28.10

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

As of late, it has definitely been a great time to be an investor in Celcuity Inc. (CELC).

5 days ago - Zacks Investment Research

- Inhibition of hyperactive RAS network signaling is nine times more effective with gedatolisib than with a PI3K-α inhibitor - - Synergistic cooperation between PI3K/mTOR and BCL signaling detected, sug...

1 week ago - Accesswire

180 Life Sciences Corp (NASDAQ: ATNF) shares are trading higher following insider buying from Marc Feldmann, a director on the company's board, and Jonathan Rothbard, the company's chief scientific offi...

Other stocks mentioned: ATNF
1 week ago - Benzinga

Celcuity broke out and soared to a nearly two-year high Friday after striking a licensing deal with Pfizer for a breast cancer treatment. Celcuity paid Pfizer $10 million in cash and stock.

1 week ago - Investors Business Daily

Celcuity Inc (NASDAQ: CELC) shares are trading higher after the company announced a worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) to develop and commercialize gedatolisib. Celcuity is a cel...

Other stocks mentioned: PRVB
1 week ago - Benzinga

Celcuity Inc (NASDAQ: CELC) has entered into a global licensing agreement with Pfizer Inc (NYSE: PFE), granting Celcuity exclusive rights to Pfizer's gedatolisib. The pan-PI3K/mTOR inhibitor is currentl...

1 week ago - Benzinga

MINNEAPOLIS--(BUSINESS WIRE)--Celcuity reports preliminary data for gedatolosib and provides corporate update

1 week ago - Business Wire

MINNEAPOLIS--(BUSINESS WIRE)-- #cancer--Celcuity has entered a global licensing agreement with Pfizer granting exclusive rights to Pfizer's cancer drug gedatolisib for breast cancer.

1 week ago - Business Wire

Celcuity Inc (NASDAQ: CELC) has announced a clinical trial collaboration with the MD Anderson Cancer Center, Novartis AG (NYSE: NVS), and Puma Biotechnology Inc (NASDAQ: PUMA) to conduct a Phase 2 clini...

Other stocks mentioned: NVS, PBYI
1 month ago - Benzinga

MINNEAPOLIS, MN / ACCESSWIRE / March 1, 2021 / Celcuity Inc. (NASDAQ:CELC), a clinical stage biotechnology company translating discoveries of new cancer sub-types into 3rd generation diagnostics and exp...

1 month ago - Accesswire

Celcuity Inc (NASDAQ: CELC) has priced its upsized underwritten public offering of 1.7 million shares at $14 per share, raising approximately $24 million in gross proceeds. The offer price is at an 11% ...

1 month ago - Benzinga

- UCLA Jonsson Comprehensive Cancer Center and Vanderbilt-Ingram Cancer Center will also participate - Study will evaluate the efficacy and safety of NERLYNX® and FASLODEX® in metastatic HR-positive, HE...

3 months ago - Accesswire

Celcuity Inc. (CELC) CEO Brian Sullivan on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Celcuity Inc. (CELC) CEO Brian Sullivan on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Celcuity Inc. (CELC) CEO Brian Sullivan on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

While domestic economic growth has been benefiting small-cap stocks until now, you should consider selling some of the stocks before entering 2020 because of poor earnings growth projections.

Other stocks mentioned: AAWW, BPFH, RRGB
1 year ago - Zacks Investment Research

Celcuity Inc. (CELC) CEO Brian Sullivan on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Celcuity, Inc. (CELC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

1 year ago - Zacks Investment Research

Celcuity's (CELC) CEO Brian Sullivan on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects.

1 year ago - Zacks Investment Research

Celcuity, Inc. (CELC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

1 year ago - Zacks Investment Research

About CELC

Celcuity Inc., a clinical stage biotechnology company, discovers cancer sub-types and therapeutic options for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. Celcuity Inc. was found... [Read more...]

Industry
Diagnostics & Research
IPO Date
Sep 20, 2017
Stock Exchange
NASDAQ
Ticker Symbol
CELC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Celcuity stock is "Buy." The 12-month stock price forecast is 30.00, which is an increase of 29.53% from the latest price.

Price Target
$30.00
(29.53% upside)
Analyst Consensus: Buy